| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 2/6 |
Labcorp Holdings Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$207.00 |
| 52 Week High | US$214.00 |
| 52 Week Low | US$175.50 |
| Beta | 1.04 |
| 11 Month Change | 7.53% |
| 3 Month Change | 0% |
| 1 Year Change | 6.15% |
| 33 Year Change | -12.77% |
| 5 Year Change | 36.18% |
| Change since IPO | 253.30% |
Recent News & Updates
Recent updates
Shareholder Returns
| N6B | DE Healthcare | DE Market | |
|---|---|---|---|
| 7D | -1.4% | -3.5% | -2.2% |
| 1Y | 6.2% | 23.7% | 13.3% |
Return vs Industry: N6B underperformed the German Healthcare industry which returned 24.7% over the past year.
Return vs Market: N6B underperformed the German Market which returned 13.6% over the past year.
Price Volatility
| N6B volatility | |
|---|---|
| N6B Average Weekly Movement | 3.0% |
| Healthcare Industry Average Movement | 3.7% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: N6B has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: N6B's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1995 | 61,975 | Adam Schechter | www.labcorp.com |
Labcorp Holdings Inc. provides laboratory services. It operates through two segments, Diagnostics Laboratories and Biopharma Laboratory Services. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid, PAP, hemoglobin A1C and vitamin D, prostate-specific antigens, sexually transmitted diseases, hepatitis C, microbiology cultures and procedures, and alcohol and other substance-abuse tests.
Labcorp Holdings Inc. Fundamentals Summary
| N6B fundamental statistics | |
|---|---|
| Market cap | €17.46b |
| Earnings (TTM) | €400.40m |
| Revenue (TTM) | €11.69b |
43.6x
P/E Ratio1.5x
P/S RatioIs N6B overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| N6B income statement (TTM) | |
|---|---|
| Revenue | US$12.71b |
| Cost of Revenue | US$9.16b |
| Gross Profit | US$3.55b |
| Other Expenses | US$3.11b |
| Earnings | US$435.50m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 5.21 |
| Gross Margin | 27.92% |
| Net Profit Margin | 3.43% |
| Debt/Equity Ratio | 83.2% |
How did N6B perform over the long term?
See historical performance and comparisonDividends
1.3%
Current Dividend Yield56%
Payout RatioDoes N6B pay a reliable dividends?
See N6B dividend history and benchmarks| Labcorp Holdings dividend dates | |
|---|---|
| Ex Dividend Date | Nov 26 2024 |
| Dividend Pay Date | Dec 13 2024 |
| Days until Ex dividend | 20 days |
| Days until Dividend pay date | 37 days |
Does N6B pay a reliable dividends?
See N6B dividend history and benchmarks